燃石醫(yī)學（納斯達克代碼：BNR）成立于2014年，公司使命為“用科學守護生命之光”，專注于為腫瘤精準醫(yī)療提供具有臨床價值的二代基因測序（NGS）。公司業(yè)務及研發(fā)方向主要覆蓋：1）基于NGS的腫瘤患病人群檢測，6年間，燃石累計檢測樣本超過25萬例，在中國擁有最高的市場份額；2）基于NGS的癌癥早檢，目前已經進入臨床驗證階段。燃石醫(yī)學于2018年7月獲國家藥品監(jiān)督管理局（NMPA）頒發(fā)的中國腫瘤NGS檢測試劑盒第一證，在體外診斷領域具有里程碑式意義。實驗室獲得廣東省臨檢中心頒發(fā)的 “高通量測序實驗室”技術審核，以及得美國CLIA和CAP實驗室質量體系資質認證。公司將繼續(xù)致力于開發(fā)創(chuàng)新可靠的NGS檢測產品，推動腫瘤精準醫(yī)療領域的發(fā)展。
?
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 250,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.